Beximco Pharmaceuticals Ltd Holdings in Company (8669V)
April 11 2023 - 10:59AM
UK Regulatory
TIDMBXP
RNS Number : 8669V
Beximco Pharmaceuticals Ltd
11 April 2023
11 April 2023
BEXIMCO PHARMACEUTICALS LIMITED
Holdings in Company
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the
Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the
fast-growing manufacturer of generic pharmaceutical products and
active pharmaceutical ingredients, notes that, following the
announcement on 31 March 2023, two shareholders in Bangladesh have
reported a further trade between one another in the Company's
Ordinary shares, which are only tradeable in Bangladesh, to the
Dhaka Stock Exchange on 10 April 2023. This trade does not concern
global depositary receipts admitted to trading on AIM in
London.
IFIC Securities Limited sold 4m Ordinary shares at a price of
TK.135.00 per share to New Dacca Industries Limited who bought the
4m Ordinary shares at a price of TK.135.00 per share between 4 and
10 April 2023.
As a result, IFIC Securities Limited no longer owns a
disclosable stake in the Company and New Dacca Industries Limited
now holds 14,345,757 Ordinary shares representing 3.22 per cent. of
the total voting rights in the Company.
For further information, please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext.20080
Mohammad Asad Ullah FCS
Executive Director & Company Secretary
Tel: 880 2 58611001, Ext. 10140
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext.20030
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of
medicines based in Bangladesh. Since its inception in 1976, the
Company remains committed to health and wellbeing of people across
all the continents by providing access to contemporary medicines.
Company's broad portfolio of generics encompasses diverse delivery
systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers,
sterile ophthalmic drops, insulins, prefilled syringes,
injectables, nebuliser solutions, oral soluble films etc. The
Company also undertakes contract manufacturing for multinational
and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Europe,
Australia, Canada, GCC and Latin America, among others and it has a
geographic footprint in more than 50 countries. More than 5500
employees are driving the company towards achieving its aspiration
to be among the most admired companies in the world.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLKZGMDDMRGFZM
(END) Dow Jones Newswires
April 11, 2023 10:59 ET (14:59 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024